In April, the FDA and the CDC announced that six women experienced rare and severe blood clots after receiving the Johnson & Johnson COVID-19 vaccine. As of April 12, 2021, more than 6.8 million doses of this specific vaccine have been administered, making the occurrence of these blood clots rare. The CDC and FDA reviewed these cases, recommending a pause in the use of this vaccine, but following a safety review, the FDA and CDC determined that the use of the Johnson & Johnson COVID-19 vaccine should be resumed. Current data shows that the vaccine’s known and potential benefits outweigh risks and that the chance of these blood clots occurring is very low.
